Progress in understanding the genetics of calcium-containing nephrolithiasis

Journal of the American Society of Nephrology

Volumn 28, Issue 3, 2017, Pages 748-759

  Sayer, John A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM OXALATE; CITRIC ACID; MAGNESIUM; OXALIC ACID; PHOSPHATE; CALCIUM;

APICAL MEMBRANE; AUTOSOMAL DOMINANT INHERITANCE; CALCIUM OXALATE STONE; CALCIUM STONE; CRYSTALLIZATION; DIET; ENVIRONMENTAL FACTOR; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC BACKGROUND; GENETIC IDENTIFICATION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; HYPERCALCIURIA; HYPEROXALURIA; HYPOCITRATURIA; INCIDENCE; MOLECULAR GENETICS; NEPHROLITHIASIS; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; REVIEW; WHOLE GENOME SEQUENCING; ANIMAL; CHEMISTRY; DISEASE MODEL; GENOME-WIDE ASSOCIATION STUDY;

ANIMALS; CALCIUM; CALCIUM OXALATE; DISEASE MODELS, ANIMAL; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KIDNEY CALCULI;

EID: 85021847845     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016050576     Document Type: Review

References (98)

1. Scales CD Jr., Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project: Prevalence of kidney stones in the United States. Eur Urol 62: 160-165, 2012.
2. Jeong IG, Kang T, Bang JK, Park J, Kim W, Hwang SS, Kim HK, Park HK: Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kidney Dis 58: 383-388, 2011.
3. El-Zoghby ZM, Lieske JC, FoleyRN, Bergstralh EJ, Li X, Melton LJ 3rd, Krambeck AE, Rule AD: Urolithiasis and the risk of ESRD. Clin JAm Soc Nephrol 7: 1409-1415, 2012.
4. Goldfarb DS, Fischer ME, Keich Y, Goldberg J: A twin study of genetic and dietary influences on nephrolithiasis: A report from the Vietnam Era Twin (VET) Registry. Kidney Int 67: 1053-1061, 2005.
5. Resnick M, Pridgen DB, Goodman HO: Genetic predisposition to formation of calcium oxalate renal calculi. N Engl J Med 278: 1313-1318, 1968.
6. Sas DJ: An update on the changing epidemiology and metabolic risk factors in pediatric kidney stone disease. Clin J Am Soc Nephrol 6: 2062-2068, 2011.
7. Romero V, Akpinar H, Assimos DG: Kidney stones: A global picture of prevalence, incidence, and associated risk factors. Rev Urol 12: E86-e96, 2010.
8. Yasui T, Iguchi M, Suzuki S, Kohri K: Prevalence and epidemiological characteristics of urolithiasis in Japan: National trends between 1965 and 2005. Urology 71: 209-213, 2008.
9. Curhan GC, Willett WC, Rimm EB, Stampfer MJ: A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 328: 833-838, 1993.
10. Prezioso D, Strazzullo P, Lotti T, Bianchi G, Borghi L, Caione P, Carini M, Caudarella R, FerraroM, Gambaro G, GelosaM, Guttilla A, Illiano E, Martino M, Meschi T, Messa P, Miano R, Napodano G, Nouvenne A, Rendina D, Rocco F, Rosa M, Sanseverino R, Salerno A, Spatafora S, Tasca A, Ticinesi A, Travaglini F, Trinchieri A, Vespasiani G, Zattoni F; CLU Working Group: Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group. Arch Ital Urol Androl 87: 105-120, 2015.
11. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC: Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 63: 1817-1823, 2003.
12. Evan A, Lingeman J, Coe FL, Worcester E: Randall's plaque: Pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int 69: 1313-1318, 2006.
13. Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M: Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111: 607-616, 2003.
14. Evan AP, Worcester EM, Coe FL, Williams J Jr., Lingeman JE: Mechanisms of human kidney stone formation. Urolithiasis 43[Suppl 1]: 19-32, 2015.
15. Moe OW, Bonny O: Genetic hypercalciuria. J Am Soc Nephrol 16: 729-745, 2005.
16. Gambaro G, Vezzoli G, Casari G, Rampoldi L, D'Angelo A, Borghi L: Genetics of hypercalciuria and calcium nephrolithiasis: From the rare monogenic to the common polygenic forms. Am J Kidney Dis 44: 963-986, 2004.
17. Hoppe B, Leumann E, von Unruh, G, LaubeN, Hesse A: Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Front Biosci 8: E437-e443, 2003.
18. Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC; Rare Kidney Stone Consortium: Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26: 2559-2570, 2015.
19. Blaschke S, Grupp C, Haase J, Kleinoeder T, Hallermann C, Troche I, Gröne HJ, Müller GA: A case of late-onset primary hyperoxaluria type 1. Am J Kidney Dis 39: E11, 2002.
20. Griffin DG: A review of the heritability of idiopathic nephrolithiasis. J Clin Pathol 57: 793-796, 2004.
21. Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, Fisher B, Spaneas L, Porath JD, Braun DA, Wassner AJ, Nelson CP, Tasic V, Sayer JA, Hildebrandt F: Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol 26: 543-551, 2015.
22. Goldfarb DS: The search for monogenic causes of kidney stones. J Am Soc Nephrol 26: 507-510, 2015.
23. Braun DA, Lawson JA, Gee HY, Halbritter J, Shril S, Tan W, Stein D, Wassner AJ, Ferguson MA, Gucev Z, Fisher B, Spaneas L, Varner J, Sayer JA, Milosevic D, Baum M, Tasic V, Hildebrandt F: Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. Clin J Am Soc Nephrol 11: 664-672, 2016.
24. Reed BY, Gitomer WL, Heller HJ, Hsu MC, Lemke M, Padalino P, Pak CY: Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. J Clin Endocrinol Metab 87: 1476-1485, 2002.
25. Bergwitz C, Roslin NM, Tieder M, Loredo-Osti JC, BastepeM, Abu-ZahraH, FrappierD, Burkett K, Carpenter TO, Anderson D, Garabedian M, Sermet I, Fujiwara TM, Morgan K, Tenenhouse HS, Juppner H: SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodiumphosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 78: 179-192, 2006.
26. Dasgupta D, Wee MJ, Reyes M, Li Y, Simm PJ, Sharma A, Schlingmann KP, Janner M, Biggin A, Lazier J, Gessner M, Chrysis D, Tuchman S, Baluarte HJ, Levine MA, Tiosano D, Insogna K, Hanley DA, Carpenter TO, Ichikawa S, Hoppe B, Konrad M, Sävendahl L, Munns CF, Lee H, Jüppner H, Bergwitz C: Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J AmSoc Nephrol 25: 2366-2375, 2014.
27. Vezzoli G, Terranegra A, Arcidiacono T, Soldati L: Genetics andcalciumnephrolithiasis. Kidney Int 80: 587-593, 2011.
28. Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, Misselwitz J, Klaus G, Kuwertz-Bröking E, Fehrenbach H, Wingen AM, Güran T, Hoenderop JG, Bindels RJ, Prosser DE, Jones G, Konrad M: Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 365: 410-421, 2011.
29. Tebben PJ, Milliner DS, Horst RL, Harris PC, Singh RJ, Wu Y, Foreman JW, Chelminski PR, Kumar R: Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: Effects of ketoconazole therapy. J Clin Endocrinol Metab 97: E423-E427, 2012.
30. Figueres ML, Linglart A, Bienaime F, Allain- Launay E, Roussey-Kessler G, Ryckewaert A, Kottler ML, Hourmant M: Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations. Am J Kidney Dis 65: 122-126, 2015.
31. Sayer JA: Re: Loss-of-function mutations of CYP24A1, the Vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. Eur Urol 68: 164-165, 2015.
32. O'Keeffe DT, Tebben PJ, Kumar R, Singh RJ, Wu Y, Wermers RA: Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: Evidence of gene dose effect. Osteoporos Int 27: 3121- 3125, 2016.
33. Sayers J, Hynes AM, Srivastava S, Dowen F, Quinton R, Datta HK, Sayer JA: Successful treatment of hypercalcaemia associated with a CYP24A1 mutation with fluconazole. Clin Kidney J 8: 453-455, 2015.
34. Dawson PA, Russell CS, Lee S, McLeay SC, van Dongen JM, Cowley DM, Clarke LA, Markovich D: Urolithiasis and hepatotoxicity are linked to the anion transporter Sat1 in mice. J Clin Invest 120: 706-712, 2010.
35. Dawson PA, Sim P, Mudge DW, Cowley D: Human SLC26A1 gene variants: A pilot study. Sci World J 2013: 541710, 2013.
36. Karniski LP, Lötscher M, Fucentese M, Hilfiker H, Biber J, Murer H: Immunolocalization of sat-1 sulfate/oxalate/bicarbonate anion exchanger in the rat kidney. Am J Physiol 275: F79-F87, 1998.
37. Gee HY, Jun I, Braun DA, Lawson JA, Halbritter J, Shril S, Nelson CP, Tan W, Stein D, Wassner AJ, Ferguson MA, Gucev Z, Sayer JA, Milosevic D, Baum M, Tasic V, Lee MG, Hildebrandt F: Mutations in SLC26A1 cause nephrolithiasis. Am J Hum Genet 98: 1228- 1234, 2016.
38. Jiang Z, Asplin JR, Evan AP, Rajendran VM, Velazquez H, Nottoli TP, Binder HJ, Aronson PS: Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet 38: 474-478, 2006.
39. Lu X, Sun D, Xu B, Pan J, Wei Y, Mao X, Yu D, Liu H, Gao B: In silico screening and molecular dynamic study of nonsynonymous single nucleotide polymorphisms associated with kidney stones in the SLC26A6 gene. J Urol 196: 118-123, 2016.
40. Monico CG, Weinstein A, Jiang Z, Rohlinger AL, Cogal AG, Bjornson BB, Olson JB, Bergstralh EJ, Milliner DS, Aronson PS: Phenotypic and functional analysis of human SLC26A6 variants in patients with familial hyperoxaluria and calcium oxalate nephrolithiasis. Am J Kidney Dis 52: 1096- 1103, 2008.
41. Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ: Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 126: 497-504, 1997.
42. McGeown MG: Heredity in renal stone disease. Clin Sci 19: 465-471, 1960.
43. Stechman MJ, Loh NY, Thakker RV: Genetics of hypercalciuric nephrolithiasis: Renal stone disease. Ann N Y Acad Sci 1116: 461-484, 2007.
44. PriéD, Ravery V, Boccon-Gibod L, Friedlander G: Frequency of renal phosphate leak among patients with calcium nephrolithiasis. Kidney Int 60: 272-276, 2001.
45. Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF, Sulem P, Halldorsson BV, de Vegt F, d'Ancona FC, den Heijer M, Franzson L, Christiansen C, Alexandersen P, Rafnar T, Kristjansson K, Sigurdsson G, Kiemeney LA, Bodvarsson M, Indridason OS, Palsson R, Kong A, Thorsteinsdottir U, Stefansson K: Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 41: 926-930, 2009.
46. Urabe Y, Tanikawa C, Takahashi A, Okada Y, Morizono T, Tsunoda T, Kamatani N, Kohri K, Chayama K, Kubo M, Nakamura Y, Matsuda K: A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible Loci at 5q35.3, 7p14.3, and 13q14.1. PLoS Genet 8: E1002541, 2012.
47. Gudbjartsson DF, Holm H, Indridason OS, ThorleifssonG, Edvardsson V, Sulem P, de Vegt, F, d'Ancona FC, den Heijer, M, Wetzels JF, Franzson L, Rafnar T, Kristjansson K, Bjornsdottir US, Eyjolfsson GI, Kiemeney LA, Kong A, Palsson R, Thorsteinsdottir U, Stefansson K: Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. PLoS Genet 6: E1001039, 2010.
48. Oddsson A, Sulem P, Helgason H, Edvardsson VO, Thorleifsson G, Sveinbjörnsson G, Haraldsdottir E, Eyjolfsson GI, Sigurdardottir O, Olafsson I, Masson G, Holm H, Gudbjartsson DF, Thorsteinsdottir U, Indridason OS, Palsson R, Stefansson K: Common and rare variants associated with kidney stones and biochemical traits. Nat Commun 6: 7975, 2015.
49. Edvardsson VO, Indridason OS, Haraldsson G, Kjartansson O, Palsson R: Temporal trends in the incidence of kidney stone disease. Kidney Int 83: 146-152, 2013.
50. Vezzoli G, Terranegra A, Rainone F, Arcidiacono T, Cozzolino M, Aloia A, Dogliotti E, Cusi D, Soldati L: Calcium-sensing receptor and calcium kidney stones. J TranslMed 9: 201, 2011.
51. Moochhala SH, Sayer JA, Carr G, Simmons NL: Renal calcium stones: Insights from the control of bone mineralization. Exp Physiol 93: 43-49, 2008.
52. Barcia JP, Strife CF, Langman CB: Infantile hypophosphatasia: Treatment options to control hypercalcemia, hypercalciuria, and chronic bone demineralization. J Pediatr 130: 825-828, 1997.
53. Prié D, Huart V, Bakouh N, Planelles G, Dellis O, Gérard B, Hulin P, Benqué-Blanchet F, Silve C, Grandchamp B, Friedlander G: Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 347: 983-991, 2002.
54. Schlingmann KP, Ruminska J, Kaufmann M, Dursun I, PattiM, Kranz B, Pronicka E, Ciara E, Akcay T, Bulus D, Cornelissen EA, Gawlik A, Sikora P, Patzer L, Galiano M, Boyadzhiev V, Dumic M, Vivante A, Kleta R, Dekel B, Levtchenko E, Bindels RJ, Rust S, Forster IC, Hernando N, Jones G, Wagner CA, Konrad M: Autosomal-recessivemutations in SLC34A1 encoding sodium-phosphate cotransporter 2A cause idiopathic infantile hypercalcemia. J AmSocNephrol 27: 604-614, 2016.
55. Vezzoli G, Terranegra A, Arcidiacono T, Gambaro G, Milanesi L, Mosca E, Soldati L; GENIAL network (Genetics and Environment in Nephrolithiasis Italian Alliance): Calcium kidney stones are associated with a haplotype of the calcium-sensing receptor gene regulatory region. Nephrol Dial Transplant 25: 2245-2252, 2010.
56. Vezzoli G, Scillitani A, Corbetta S, Terranegra A, Dogliotti E, Guarnieri V, Arcidiacono T, Paloschi V, Rainone F, Eller-Vainicher C, Borghi L, Nouvenne A, Guerra A, Meschi T, Allegri F, Cusi D, Spada A, Cole DE, Hendy GN, Spotti D, Soldati L: Polymorphisms at the regulatory regions of the CASR gene influence stone risk in primary hyperparathyroidism. Eur J Endocrinol 164: 421-427, 2011.
57. Vezzoli G, Terranegra A, Aloia A, Arcidiacono T, Milanesi L, Mosca E, Mingione A, Spotti D, Cusi D, Hou J, Hendy GN, Soldati L, Paloschi V, Dogliotti E, Brasacchio C, Dell'Antonio G, Montorsi F, Bertini R, Bellinzoni P, Guazzoni G, Borghi L, Guerra A, Allegri F, Ticinesi A, Meschi T, Nouvenne A, Lupo A, Fabris A, Gambaro G, Strazzullo P, Rendina D, De Filippo, G, BrandiML, Croppi E, Cianferotti L, Trinchieri A, Caudarella R, Cupisti A, Anglani F, Del Prete, D; GENIAL network (Genetics and Environment in Nephrolithiasis Italian Alliance): Decreased transcriptional activity of calcium-sensing receptor gene promoter 1 is associated with calciumnephrolithiasis. J Clin Endocrinol Metab 98: 3839-3847, 2013.
58. Mossetti G, Rendina D, Viceconti R, Manno G, Guadagno V, Strazzullo P, Nunziata V: The relationship of 39 vitamin D receptor haplotypes to urinary supersaturation of calcium oxalate salts and to age at onset and familial prevalence of nephrolithiasis. Nephrol Dial Transplant 19: 2259-2265, 2004.
59. Bid HK, Kumar A, Kapoor R, Mittal RD: Association of vitamin D receptor-gene (FokI) polymorphism with calcium oxalate nephrolithiasis. J Endourol 19: 111-115, 2005.
60. Gao B, Yasui T, Itoh Y, Li Z, Okada A, Tozawa K, Hayashi Y, Kohri K: Association of osteopontin gene haplotypes with nephrolithiasis. Kidney Int 72: 592-598, 2007.
61. Liu CC, Huang SP, Tsai LY, Wu WJ, Juo SH, Chou YH, Huang CH, Wu MT: The impact of osteopontin promoter polymorphisms on the risk of calcium urolithiasis. Clin Chim Acta 411: 739-743, 2010.
62. Gao B, Yasui T, Itoh Y, Tozawa K, Hayashi Y, Kohri K: A polymorphism of matrix Gla protein gene is associated with kidney stones. J Urol 177: 2361-2365, 2007.
63. Lu X, Gao B, Liu Z, Tian X, Mao X, Emmanuel N, Zhu Q, Xiao C: A polymorphism of matrix Gla protein gene is associated with kidney stone in the Chinese Han population. Gene 511: 127-130, 2012.
64. Tsai FJ, Lin CC, Lu HF, Chen HY, Chen WC: Urokinase gene 39-UTR T/C polymorphism is associated with urolithiasis. Urology 59: 458- 461, 2002.
65. Ozturk M, Kordan Y, Cangul H, Dogan HS, Kilicarslan H, Vuruskan H, Oktay B: Association of urokinase gene 39-UTR T/C polymorphism with calcium oxalate urolithiasis in children. Int Urol Nephrol 40: 563-568, 2008.
66. Toka HR, GenoveseG, Mount DB, PollakMR, Curhan GC: Frequency of rare allelic variation in candidate genes among individuals with low and high urinary calcium excretion. PLoS One 8: E71885, 2013.
67. Karet FE, Finberg KE, Nelson RD, Nayir A, Mocan H, Sanjad SA, Rodriguez-Soriano J, Santos F, Cremers CW, Di Pietro A, Hoffbrand BI, Winiarski J, Bakkaloglu A, Ozen S, Dusunsel R, Goodyer P, Hulton SA, Wu DK, Skvorak AB, Morton CC, CunninghamMJ, Jha V, Lifton RP: Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet 21: 84-90, 1999.
68. Dhayat NA, Schaller A, Albano G, Poindexter J, Griffith C, Pasch A, Gallati S, Vogt B, Moe OW, Fuster DG: The vacuolar H+-ATPase B1 subunit polymorphism p.E161K associates with impaired urinary acidification in recurrent stone formers. J AmSocNephrol 27: 1544-1554, 2016.
69. Coe FL, Evan AP, Worcester EM, Lingeman JE: Three pathways for human kidney stone formation. Urol Res 38: 147-160, 2010.
70. Arcidiacono T, Mingione A, Macrina L, Pivari F, Soldati L, Vezzoli G: Idiopathic calcium nephrolithiasis: A review of pathogenic mechanisms in the light of genetic studies. Am J Nephrol 40: 499-506, 2014.
71. Tiselius HG: A hypothesis of calcium stone formation: An interpretation of stone research during the past decades. Urol Res 39: 231-243, 2011.
72. Albright F, Henneman P, Benedict PH, Forbes AP: Idiopathic hypercalciuria: A preliminary report. Proc R Soc Med 46: 1077- 1081, 1953.
73. Coe FL, Parks JH, Moore ES: Familial idiopathic hypercalciuria. N Engl J Med 300: 337-340, 1979.
74. Sayer JA: The genetics of nephrolithiasis. Nephron Exp Nephrol 110: E37-e43, 2008.
75. Sayer JA: Renal stone disease. Nephron, Physiol 118: 35-44, 2011.
76. Curhan GC, Willett WC, Speizer FE, Stampfer MJ: Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59: 2290-2298, 2001.
77. Kuo RL, Lingeman JE, Evan AP, Paterson RF, Parks JH, Bledsoe SB, Munch LC, Coe FL: Urine calcium and volume predict coverage of renal papilla by Randall's plaque. Kidney Int 64: 2150-2154, 2003.
78. Taguchi K, Hamamoto S, Okada A, Unno R, Kamisawa H, Naiki T, Ando R, Mizuno K, Kawai N, Tozawa K, Kohri K, Yasui T: Genome-wide gene expression profiling of randall's plaques in calcium oxalate stone formers [published online ahead of print June 13, 2016]. J Am Soc Nephrol.
79. Sakhaee K, Poindexter J, Aguirre C: The effects of bariatric surgery on bone and nephrolithiasis. Bone 84: 1-8, 2016.
80. Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW: Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 69: 691- 698, 2006.
81. Jaenisch R, Bird A: Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet 33[Suppl]: 245-254, 2003.
82. Dow JA, Romero MF: Drosophila provides rapid modeling of renal development, function, and disease. Am J Physiol Renal Physiol 299: F1237-F1244, 2010.
83. Chi T, Kim MS, Lang S, Bose N, Kahn A, Flechner L, Blaschko SD, Zee T, Muteliefu G, Bond N, Kolipinski M, Fakra SC, Mandel N, Miller J, Ramanathan A, KillileaDW, Brückner K, Kapahi P, Stoller ML: A Drosophila model identifies a critical role for zinc in mineralization for kidney stone disease. PLoS One 10: E0124150, 2015.
84. Landry GM, Hirata T, Anderson JB, Cabrero P, Gallo CJ, Dow JA, Romero MF: Sulfate and thiosulfate inhibit oxalate transport via a dPrestin (Slc26a6)-dependent mechanism in an insect model of calcium oxalate nephrolithiasis. Am J Physiol Renal Physiol 310: F152-F159, 2016.
85. Elizondo MR, Arduini BL, Paulsen J, MacDonald EL, Sabel JL, Henion PD, Cornell RA, Parichy DM: Defective skeletogenesis with kidney stone formation in dwarf zebrafish mutant for trpm7. Curr Biol 15: 667-671, 2005.
86. Elizondo MR, Budi EH, Parichy DM: Trpm7 regulation of in vivo cation homeostasis and kidney function involves stanniocalcin 1 and fgf23. Endocrinology 151: 5700-5709, 2010.
87. Ryazanova LV, Rondon LJ, Zierler S, Hu Z, Galli J, Yamaguchi TP, Mazur A, Fleig A, Ryazanov AG: TRPM7 is essential for Mg(2+) homeostasis in mammals. Nat Commun 1: 109, 2010.
88. Bilbault H, Haymann JP: Experimental models of renal calcium stones in rodents. World J Nephrol 5: 189-194, 2016.
89. Wu XR: Interstitial calcinosis in renal papillae of genetically engineered mouse models: Relation to Randall's plaques. Urolithiasis 43 [Suppl 1]: 65-76, 2015.
90. Ohana E, Shcheynikov N, Moe OW, Muallem S: SLC26A6 and NaDC-1 transporters interact to regulate oxalate and citrate homeostasis. J Am Soc Nephrol 24: 1617- 1626, 2013.
91. Breiderhoff T, Himmerkus N, Stuiver M, Mutig K, Will C, Meij IC, Bachmann S, Bleich M, Willnow TE, Müller D: Deletion of claudin-10 (Cldn10) in the thick ascending limb impairs paracellular sodium permeability and leads to hypermagnesemia and nephrocalcinosis. Proc Natl Acad Sci USA 109: 14241-14246, 2012.
92. Hoenderop JA, van Leeuwen, JA, van der Eerden, BA, Kersten FA, van der Kemp, AA, Merillat AA, Waarsing JA, Rossier BA, Vallon VA, Hummler EA, Bindels RA: Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 112: 1906-1914, 2003.
93. van der Eerden, BC, Hoenderop JG, de Vries, TJ, Schoenmaker T, Buurman CJ, Uitterlinden AG, Pols HA, Bindels RJ, van Leeuwen, JP: The epithelial Ca2+ channel TRPV5 is essential for proper osteoclastic bone resorption. Proc Natl Acad Sci USA 102: 17507-17512, 2005.
94. Loh NY, Bentley L, Dimke H, Verkaart S, Tammaro P, Gorvin CM, Stechman MJ, Ahmad BN, Hannan FM, Piret SE, Evans H, Bellantuono I, Hough TA, Fraser WD, Hoenderop JG, Ashcroft FM, Brown SD, Bindels RJ, Cox RD, Thakker RV: Autosomal dominant hypercalciuria in a mouse model due to a mutation of the epithelial calcium channel, TRPV5. PLoS One 8: E55412, 2013.
95. Renkema KY, Lee K, Topala CN, Goossens M, Houillier P, Bindels RJ, Hoenderop JG: TRPV5 gene polymorphisms in renal hypercalciuria. Nephrol Dial Transplant 24: 1919- 1924, 2009.
96. Frick KK, Krieger NS, Bushinsky DA: Modeling hypercalciuria in the genetic hypercalciuric stone-forming rat. Curr Opin Nephrol Hypertens 24: 336-344, 2015.
97. Krieger NS, Asplin JR, Frick KK, Granja I, Culbertson CD, Ng A, Grynpas MD, Bushinsky DA: Effect of potassium citrate on calcium phosphate stones in a model of hypercalciuria. J Am Soc Nephrol 26: 3001- 3008, 2015.
98. Hoopes RR Jr., Middleton FA, Sen S, Hueber PA, Reid R, Bushinsky DA, Scheinman SJ: Isolation and confirmation of a calcium excretion quantitative trait locus on chromosome 1 in genetic hypercalciuric stone-forming congenic rats. J Am Soc Nephrol 17: 1292-1304, 2006.